- In March 2023, Celtaxsys concluded Phase 2 of a pragmatic, multi-arm, adaptive, blinded, randomized placebo-controlled platform trial for Acebilustat (CTX-4430). The trial aimed to assess various investigational therapeutics' efficacy in reducing time to disease resolution or viral load cessation in COVID-19 outpatients, compared to standard supportive care. This approach offers insights into potential treatments for managing COVID-19 outside of hospital settings
Frequently Asked Questions
The market is segmented based on Segmentation, By Drugs (Montelukast, Zafirlukast, Zileuton, and Others), Indication (Asthma, COPD, Allergic Rhinitis, and Others), End-Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Leukotriene Inhibitors Market size was valued at USD 2.31 USD Billion in 2023.
The Global Leukotriene Inhibitors Market is projected to grow at a CAGR of 6.22% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
